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Abstract
Lymphocyte enhancer binding factor 1 (LEF-1) plays a crucial role in B lineage development and is only expressed in B cell
precursors as B cell differentiation into mature B and plasma cells silences its expression. Chronic lymphocytic leukemia
(CLL) cells aberrantly express LEF-1 and its expression is required for cellular survival. We hypothesized that modification of
the differentiation status of CLL cells would result in loss of LEF-1 expression and eliminate the survival advantage provided
by its aberrant expression. In this study, we first established a methodology that induces CLL cells to differentiate into
immunoglobulin (Ig) secreting cells (ISC) using the TLR9 agonist, CpG, together with cytokines (CpG/c). CpG/c stimulation
resulted in dramatic CLL cell phenotypic and morphologic changes, expression of cytoplasmic Ig, and secretion of light
chain restricted Ig. CpG/c stimulation also resulted in decreased CLL cell LEF-1 expression and increased Blimp-1 expression,
which is crucial for plasma cell differentiation. Further, Wnt pathway activation and cellular survival were impaired in
differentiated CLL cells compared to undifferentiated CLL cells. These data support the notion that CLL can differentiate into
ISC and that this triggers decreased leukemic cell survival secondary to the down regulation of LEF-1 and decreased Wnt
pathway activation.
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Introduction
Chronic lymphocytic leukemia (CLL) is a clonal expansion of
neoplastic mature B lymphocytes and is the most prevalent
lymphoid malignancy in the United States. CLL is effectively
treated with chemo-immunotherapy although CLL remains an
incurable malignancy with conventional management. To better
understand this disease, state of the art genomic methodologies
have been employed[1,2,3,4] to identify genes involved in disease
pathogenesis. Despite new insights emerging from genome-wide
studies, there is still a need to further explore novel therapeutic
alternatives to improve the treatment of this malignancy.
We and others have previously shown CLL cells aberrantly
express the transcription factor lymphoid enhancer binding
factor-1 (LEF-1) and rely on this factor for their survival.[5,6]
LEF-1 is a target gene and central mediator of the wingless-type
MMTV integration site (Wnt) signaling pathway, which plays an
active role in the biology of CLL.[7] While LEF-1 is critical
during normal B cell development in the bone marrow,[8] LEF-1
expression is restricted to developing B cells, with expression
turned off at later stages of B lineage development, i.e., mature B
cells and plasma cells.[9] In a mechanism(s) yet to be identified,
CLL cells have reacquired expression of this developmentally
important survival factor. We hypothesized that differentiation of
leukemic B cells into immunoglobulin (Ig) secreting cells (ISC)
would result in loss of LEF-1 expression and decreased leukemic
cell survival.
Agents that induce terminal differentiation of leukemic cells
have been utilized therapeutically with the greatest successes
realized using all-trans retinoic acid for acute promyelocytic
leukemia and interferon-a for hairy cell leukemia.[10,11] This
strategy relies on the fact that leukemic cells are blocked at a
particular stage in their development and are not truly terminally
differentiated. Several agents are able to induce leukemic cells to
overcome their block of differentiation resulting in inhibition of
proliferation and an increase in apoptotic cell death. This
alternative differentiation strategy has been combined with
traditional cytotoxic therapies to increase the efficacy of treatment.
Of relevance to this study, there has been an interest in utilizing
toll like receptor (TLR) agonists in the treatment of hematologic
malignancies.[12,13,14] TLRs are a family of pattern recognition
receptors involved in the detection of pathogen associated
molecular patterns and other ‘‘danger’’ signals. This large class
of receptors plays a crucial role in both innate and adaptive
immunity. The rationale for their use in hematologic malignancies
has centered on the induction of and sensitization to the anti-
leukemic immune response, as well as potential direct anti-
leukemic properties of these agents.[14]
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agonist, CpG, with proliferation, upregulation of costimulatory
molecules, and induction of apoptosis.[15,16,17] However, to our
knowledge there has been no study to date that has evaluated the
ability of these agents to induce CLL B cell differentiation into ISC.
Previous studies suggest that CLL cells can secrete antibody in
response to certain stimuli such as pokeweed mitogen, or other
stimuli with cytokines.[18,19,20,21,22] TLR agonists, along with
cytokines IL-2 and IL-15, are well characterized in their ability to
induce terminal differentiation of normal mature B cells.[23] We
hypothesized that CpG along with cytokines IL-2 and IL-15 (CpG/
c) could be used asa tool to induceCLLcelldifferentiation and alter
prosurvival signaling byLEF-1 andtheWntpathway. Inthe present
study, we addressed two critical questions; (1) do CLL cells lose
LEF-1 expression upon differentiation into ISC; and (2) do CLL
cells that differentiate into ISC lose LEF-1 prosurvival signaling and
exhibit decreased survival?
Methods
Ethics statement and patient cohort
Mayo Clinic Institutional Review Board (IRB) approval was
obtained for use of human blood from healthy donors. The IRB
reviewed our request to use blood from healthy donors and
specifically waived the need for informed consent for our protocol
due to the ruling that this is waste material generated during blood
donation. In further support of the IRB waiver of informed
consent, these specific patient samples arrive de-identified in the
laboratory. Regarding CLL patients, Mayo Clinic IRB approval
was obtained and blood was only used from patients providing
written informed consent in accord with Helsinki protocol. Patient
clinical and relevant prognostic factors are summarized in Table 1.
Cell isolation and culture
Peripheral blood mononuclear cells (PBMC) from CLL patients
or healthy donors were separated from heparinized venous blood
by Ficoll density gradient centrifugation. The PBMC used in this
study were generally greater than 90% CLL B cells as determined
by CD19/CD5 positivity. Leukemic cells were cultured in serum-
free adoptive immunotherapy media-V (AIM-V) medium (Gibco-
Invitrogen). For CLL B cell activation experiments, cells were
cultured for 5 days in AIM-V media or AIM-V media
supplemented with 2.5 mg/ml CpG ODN 2006 (provided by core
Mayo Clinic facility) with or without 94 IU/ml human IL-2
(Peprotech), 10 ng/ml human IL-15 (Peprotech), and 13 mM beta-
mercaptoethanol. Further CLL B cell activation experiments
utilized 12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma) at
10 ng/ml or interferon-a 2b (Schering Corp.) at 1000 IU/ml.
Human CD4+T cells were isolated from healthy donor PBMC by
immunomagnetic selection using T cell enrichment kits (StemCell
Technologies) and incubated with CLL B cells at a ratio of 1:2 in
plates pre-coated with PBS containing 10 mg/ml of anti-CD3
(R&D) and anti-CD28 (BD) stimulating antibodies. All cells were
maintained in appropriate media at 37uC in an atmosphere
containing 95% air and 5% CO2.
Quantitative polymerase chain reaction (qPCR)
Sense and antisense primers to LEF1 (forward- 59-GAC GAG
ATG ATC CCC TTC AA-39/reverse- 59-AGG GCT CCT GAG
AGG TTT GT-39) and 18 s rRNA (forward- 59-AAA CGG CTA
CCA CAT CCA AG-39/reverse- 59-CCT CCA ATG GAT CCT
CGT TA-39) were designed using Primer3. PRDM1 primers were
purchased from SABiosciences. Total RNA isolated by the Trizol
method (Invitrogen) was reverse transcribed to cDNA using the
1 st Strand cDNA Synthesis kit (GE Healthcare). One ml of cDNA
was amplified using the SYBR Green/Rox PCR reagent
(SABiosciences) in a total volume of 20 ml, which included 5 pM
of each primer and 1 x SYBR Green Mastermix. Amplification
was carried out using a 7900 HT Applied Biosystems fast real-time
PCR system as follows: denaturation at 95uC for 15 min; 40 cycles
of 15 s at 95uC; 60 s at 60uC and a melting curve cycle. Melting
temperature and quantitative analysis was performed using SDS
RQ software. Relative fold change was normalized against 18 s




Cells were lysed for 30 min on ice in lysis buffer containing
10 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5%
deoxycholate, 0.1% SDS, 5 mM EDTA, complete mini protease
inhibitor cocktail (Roche), and phosSTOP phosphatase inhibitor
cocktail (Roche). An equal volume of Laemmli sample buffer (Bio-
Rad) was added before boiling for 5 min. Lysates were subjected
to electrophoresis through a 10% Tris-HCl polyacrylamide gel
using Tris-Glycine-SDS buffer. Proteins were transferred to PVDF
membranes (Millipore) and blocked with 25 mM Tris-HCl
(pH 7.2), 150 mM NaCl, and 0.1% Tween 20 (TBST) plus
5.0% Blotto (ISC BioExpress). The blot was probed with anti-
LEF-1 antibody (Cell Signaling Technology) at a 1:1000 dilution,
or anti-b-actin antibody (Novus) at a 1:5000 dilution. After three
washes with TBST, donkey anti-rabbit or sheep anti-mouse HRP
secondary (GE Healthcare) was used at a 1:2000 dilution. After
washing, SuperSignal (Pierce) Chemiluminescent substrate was
then used to detect proteins.
Flow cytometry
Cells were washed in FACS buffer (PBS+1% FCS) and
incubated with conjugated primary antibody for 10 minutes at
room temperature. Antibodies included anti-CD19 APC and anti-
CD5 PE (BD Biosciences). For intracellular staining, cells were
fixed in 4% formaldehyde/PBS at 37uC for 10 minutes and
permeabilized by resuspending in 90% methanol and incubation
on ice for 30 minutes. Cells were incubated with primary anti-
LEF1 antibody (Cell Signaling) or isotype control for 1 hr, washed,
and incubated with secondary Alexa-488 goat anti-rabbit IgG
(Invitrogen) for 30 minutes. Cells were then analyzed on a BD
FACSCalibur and data analysis was performed using FlowJo
software (TreeStar).
ELISA
Following 5 days of culture under the conditions described
above, cell free culture supernatants were collected and analyzed
for levels of secreted Ig using IgM, IgG, kappa, and lambda
ELISA. Briefly, 96-well microtiter plates (Nalge Nunc Interna-
tional) were independently coated with anti-IgG, anti-IgM
(BioSource International), anti-kappa, or anti-lambda (Bethyl
Laboratories) antibodies. Plates were then blocked with 1x casein
(BioFX Laboratories). After several washes, culture supernatants
were added to coated plates and incubated for 2 h. Igs were
detected colorimetrically using anti-IgG, anti-IgM (BioSource
International), anti-kappa, or anti-lambda (Bethyl Laboratories)
HRP-labeled antibodies and a Molecular Devices microplate
reader. Standard curves were generated to quantitate ELISA
results using known amounts of purified human IgG and IgM
(Jackson ImmunoResearch Laboratories), as well as purified
kappa, and lambda light chain proteins (Bethyl Laboratories). o-
Phenylenediamine dihydrochloride ELISA substrate for HRP
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Pierce.
TCF/LEF dual luciferase assay
TCF/LEF reporter plasmids were purchased from SA Biosci-
ences. The positive reporter plasmid has TCF/LEF consensus
binding sites that drive expression of firefly luciferase, and the
negative reporter lacks TCF/LEF binding sites. These plasmids
were introduced along with a constitutively expressed renilla
luciferase plasmid into CLL cells as previously described.[5] CLL
cells were cultured for 5 days in CpG/c or control media,
separated by Ficoll density gradient centrifugation, nucleofected,
and then cultured in control media for 48 hours before being
harvested. Positive reporter firefly luciferase values were normal-
ized to constitutively expressed renilla luciferase and a negative
reporter fold change of 1.
Cell survival analysis
Cells were either unstimulated or stimulated as described above
for 5 days prior to isolation of viable cells using Ficoll density
gradient centrifugation. Ficoll-isolated cells were evaluated by
trypan blue exclusion to measure cell viability and purity was
evaluated by CD19/CD5 FACS analysis before culturing for an
additional 48 hours in AIM-V media. Purity ranged from 90–97%
CLL cells of Ficoll-isolated cells from 5 day stimulated cultures.
On day 7, cell survival was measured by Annexin-FITC (BD
Biosciences) and propidium iodide (PI) staining and analyzed by
flow cytometry.
Cytoplasmic Ig (cIg) and morphological studies
CLL cell morphology was analyzed using cytospin preparations
of the cells on glass slides made using a Thermo Shandon Cytospin
2 and stained by standard Wright-Giemsa (Fisher). For cIg
staining, cells were fixed in 95% ethanol for 5 minutes, air dried,
and then permeabilized with 0.1% NP-40 in PBS. Cells were then
stained with a FITC-conjugated F(ab’)2 polyclonal antibody with
specificity for human IgM, IgG, and IgA (Biosource International)
at a dilution of 1:100 in PBS with 5% serum for 45 min at 37u C.
The cells were then washed with 0.1% NP-40 in PBS before
adding mounting media containing either DAPI or PI and
coverslipped (Vector Labs). Cells were viewed by light microscopy
(Olympic Provus AX70; Olympus) and images were acquired
using an Olympus DP71 microscope digital camera equipped with
Olympus DP Manager Software. Using Microsoft PowerPoint, the
brightness of all images were uniformly decreased 7%.
[
3H]-Thymidine proliferation assay
Proliferation assays were performed as described previously,[24]
with the exception that 2610
5 CLL cells were stimulated or not as
described above in 96 well plates for 72 hours before being pulsed with
1mCi of tritiated thymidine (Amersham). Cells were then cultured for
18 hours, harvested and counted using liquid scintillation spectroscopy.
Table 1. Patient cohort characteristics.
Patient Age/Sex Stage CD38 ZAP-70 IGHV gene/ % Mutation FISH Prior Tx*
1 60/M I neg neg 3–53/12% 13q- no
2 75/M II neg POS 3–33/9.8% 13q- no
3 68/F 0 neg neg 3–7/7.3% Normal no
4 66/M 0 neg neg 4–59/11.7% 13q- no
5 69/M IV neg POS 1–3/0.0% Normal PCR
6 45/M I POS neg 7–4/0.0% 13q- no
7 56/M II neg POS 1–69/0.0% 11q- FCR
8 56/M II neg POS 3–23/2.6% 13q- no
9 56/F I neg neg 1–18/0.0% 11q-, 13q- AR
10 65/M 0 neg neg 4–4/12.5% 13q- no
11 58/M 0 neg neg 4–39/12.8% Normal no
12 64/F I neg POS 3–9/0.0% Normal no
13 74/F I neg neg 4–34/0.0% Trisomy 12 no
14 86/F 0 neg neg 3–7/6.3% Normal no
15 64/F 0 neg neg 4–34/6% 13q- no
16 69/M I neg neg 1–08/4.5% 13q-62n o
17 78/F 0 neg neg 1–08/4.3% 13q-62n o
18 58/M II neg neg 3–11/8.1% Normal no
19 72/M II neg POS 3–49/0.0% 17p-, 13q- no
20 49/M I neg POS 1–69/0.0% Normal no
21 60/M 0 neg neg 3–7/4.9% 13q- no
22 70/M 0 POS neg 3–30/0.0% Trisomy 12 no
23 81/F II neg POS 3–07/4.5% 17p-, 13q-, t(14;18) AR, PAR
24 85/F 0 neg neg 1–18/4.7% t(14;18) no
25 73/M IV POS POS 5–51/0.0% Trisomy 12, t(14;19), +14q32 (IGH+) PR, PCR
*Treatments abbreviated as follows; P is pentostatin, C is cyclophosphamide, R is rituximab, F is fludarabine, and A is alemtuzumab.
doi:10.1371/journal.pone.0026056.t001
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[
3H]-Thymidine proliferation assays, TCF/LEF reporter assays,
and ELISA and survival data were analyzed using a paired t-
statistic analysis approach.
Results
CpG/c stimulated CLL cells proliferate and develop a
plasmacytoid morphology
Previous studies have used CpG stimulation as a tool to induce
primary CLL B cell proliferation[16,17,25] and because of this
property, CpG stimulation has utility in metaphase analysis of
leukemic B cells.[26,27] Although the ability of CpG stimulation to
induce CLL cell differentiation has not been previously reported, it
has been shown that CpG/c is effective in inducing the
differentiation of normal B cells into ISC.[23,28] Because the
primary goal of our study was to assess the impact of leukemic B cell
differentiation on LEF-1 expression, we first wished to determine if
CpG/c could similarly induce CLL B cell differentiation. Initially,
we analyzed the effects of CpG vs CpG/c on CLL B cell
proliferation and observed that CpG/c stimulates a much greater
proliferative response than CpG alone (n=6, p=0.020, Fig.1A).
We reasoned that CpG in concert with cytokines might also have
the potential to induce CLL cell differentiation into ISC.
To address this possibility, we took advantage of the knowledge
that ISC are large cells with a characteristic morphology that
includes an abundant cytoplasm and an eccentrically located oval
nucleus. Indeed, CLL B cells stimulated for 5 days with CpG/c,
took on the characteristic morphology of ISC (Fig. 1B). These
data suggest that CpG/c stimulation could induce CLL B cell
differentiation into ISC.
CpG/c stimulated CLL B cells increase cIg expression and
secrete light chain restricted Ig
CLL B cell Ig expression is typically restricted to the cell
membrane and the majority of patients express membrane IgM
and IgD, although at varying levels. Because a hallmark feature of
Ig secreting differentiated B cells is the appearance of cIg and
switch from membrane expression to secreted forms of Ig, we next
evaluated these aspects in CpG/c activated CLL cells. Stimulated
CLL cells increased expression of cIg compared to control treated
cells as detected by intracellular immunofluorescence staining for
Figure 1. CpG/c stimulation induces proliferation and plasmacytoid morphology in CLL cells. A. Detection of proliferation in leukemic B
cells from 6 CLL patients by [
3H]-thymidine incorporation. (*p=.02; error bars represent standard error of the mean) B. Morphologic analysis of
leukemic B cells on days 0, 3, and 5 after CpG/c stimulation as revealed by Wright Giemsa staining.
doi:10.1371/journal.pone.0026056.g001
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staining for cytoplasmic Ig in CpG/c stimulated leukemic B cells. B. ELISA detection of IgM and IgG levels in cell free culture supernatants from 14
patients in unstimulated or CpG/c treated CLL cultures after 5 days. (*p=.02; error bars represent standard error of the mean) C. ELISA detection of
kappa and lambda light chain Ig levels in cell free culture supernatants from 7 patients in nil or CpG/c treated CLL cultures after 5 days.
doi:10.1371/journal.pone.0026056.g002
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stimulation caused an increase in secreted IgM in the majority of
CLL patients, while IgG levels remained low in both stimulated
and control supernatants. CpG/c stimulated samples secreted an
average of 1265 ng/ml of IgM compared to 156 ng/ml without
treatment (n=14, p=.029, Fig. 2B). In order to address the
possibility that residual normal B cells were the primary source of
the secreted IgM, we next evaluated the k and l light chain usage
of the secreted Ig. Figure 2C importantly demonstrates that
CpG/c stimulated CLL cells secreted either k or l light chains but
not both, which would be expected if normal polyclonal B cells
were the source of secreted Ig. In addition, the patterns of light
chain secretion precisely matched the known light chain usage of
the patients’ leukemic B cells in all cases tested. These data support
the conclusion that CpG/c stimulation is able to induce CLL B
cell differentiation into ISC.
CLL B cells induced to differentiate into ISC exhibit
decreased LEF1 and increased expression of PRDM1
Plasma cell differentiation has been well characterized and
shown to require expression of a number of master regulators, with
one of the most well characterized being BLIMP1 (gene name
PRDM1). Thus, we next evaluated the expression levels of PRDM1
and LEF1 in CpG/c stimulated CLL cells that had acquired the
ability to secrete Ig. In further support of our conclusion that this
stimulation induces CLL B cell differentiation, we observed that
CpG/c stimulated cells acquired increased expression of PRDM1
(Fig. 3A, left). Importantly, we also observed a concomitant
decrease in LEF1 expression as detected by qPCR (Fig. 3A, right).
Further, decreased LEF-1 expression was also observed at the
protein level as revealed by western blot and intracellular FACS
analysis (Figs. 3B and 3C, respectively). However, we also
observed significant patient to patient variability in the decrease of
LEF-1 protein expression induced by CpG/c. Interestingly, the
level of Ig secretion by differentiated CLL cells was observed to
inversely correlate with the level of LEF-1 expression remaining in
differentiated CLL cells (n=14, R
2=0.505, Fig. 3D). These data
support the conclusion that differentiation of CLL B cells into ISC
leads to the downregulation of LEF-1 expression.
Differentiated CLL B cells exhibit decreased activation of
the Wnt pathway and decreased survival
Previously, we have shown that CLL B cells exhibit aberrant
activation of the canonical Wnt signaling pathway as detected
using the TCF/LEF dual luciferase reporter assay, while healthy
donor B cells lack activation of this pathway.[5] Because LEF-1 is
a central mediator of the Wnt pathway and because differentiation
of CLL B cells into ISC resulted in decreased expression of LEF-1,
we next evaluated the level of Wnt pathway activation in these
cells. Indeed, Ig secreting differentiated CLL cells were observed
to have decreased activation of the TCF/LEF dual luciferase
reporter assay compared to untreated CLL cells. The average fold
change in reporter activity was 6.9 for ISC differentiated CLL vs
17.5 for untreated CLL cells (n=3, p=0.0098, Fig. 4A). This is a
60% decrease in the level of Wnt pathway activation following
CLL B cell differentiation. These data support the conclusion that
differentiation of CLL cells leads to a robust decrease in Wnt-
mediated pro-survival signaling.
LEF-1 and the Wnt pathway are known to regulate survival in
numerous cell types.[29,30] We and others have previously shown
that expression of this transcription factor by CLL cells is required
for cellular survival.[5,6] Therefore, we next wanted to evaluate
whether ISC differentiated CLL cells that have decreased LEF-1
expression, also display decreased in vitro survival. To overcome
possible early effects of CpG/c stimulation on apoptosis, we
differentiated the cells for 5 days before separating live cells by
Ficoll gradient centrifugation and replating equal numbers of
differentiated or control cells in AIM-V media for an additional
48 hour incubation period. At this point, cell survival was
analyzed and our data demonstrate that ISC differentiated CLL
B cells exhibited poorer survival than did untreated CLL cells.
Untreated CLL cells had an average of 86.4% surviving cells
compared to an average of 39.4% surviving cells for differentiated
cells (n=3, p=0.0039, Fig. 4B). Thus, there was a 55% average
decrease in survival following CLL B cell differentiation into ISC.
These data support the conclusion that differentiation of CLL cells
leads to a decrease in cell survival.
Multiple agents are able to induce CLL B cell
differentiation and subsequent decreases in LEF-1
expression
Previously, others had reported the ability of TPA and T cell
dependent pokeweed mitogen to induce CLL cell differentiation
into ISC.[19,20] Because CpG/c has the ability to differentiate
CLL cells into ISC and downregulate LEF-1, we questioned
whether other agents might also possess this ability. To address this
point, we tested the ability of CpG alone, CpG/c, TPA,
interferon-a, and activated T cells to stimulate CLL cell Ig
secretion. TPA stimulation induced the largest increase in Ig
secretion, but all stimulations led to a variable increase in Ig
secretion (n=6, Fig. 5A). We next evaluated the ability of these
stimulations to induce down regulation of LEF-1. Of note, TPA
was able to induce the largest decrease in LEF-1 levels, paralleling
the robust Ig secretion stimulated by this agent. Moreover, each of
the other stimuli also led to decreases in LEF-1 levels, with the
degree of LEF-1 expression being associated with the overall levels
of secreted Ig (n=6, Fig. 5B). These data support the conclusion
that a variety of biological agents capable of stimulating CLL cell
differentiation lead to a decrease in LEF-1 expression.
Discussion
Previously, we identified a pathogenic role for LEF-1 and the
Wnt pathway in CLL B cells. In this study, we demonstrate that
the differentiation of CLL cells into ISC leads to a decrease in
LEF-1 expression and a decrease in TCF/LEF reporter activation.
Although other investigators have shown that CLL cells can be
induced to differentiate into ISC using a variety of stimu-
li,[18,19,20,21,22] we show for the first time that differentiated
CLL cells exhibit diminished cell survival. Our study supports the
Figure 3. CpG/c stimulated CLL B cells decrease LEF-1 expression and increase PRDM1 expression. A. Detection of PRDM1 (left) and LEF1
(right) mRNA levels by qPCR in 3 CLL patients in nil or CpG/c treated CLL cultures after 5 days. Transcript levels were normalized to 18 s rRNA and
relative fold change was calculated using the 2ˆ2DDCT method. B. Representative western blot analysis of LEF-1 full length and DN LEF-1 isoforms in B
cells from 3 CLL samples in nil or CpG/c treated CLL cultures after 5 days of culture; b-actin shown as a loading control of samples. C. Representative
intracellular FACS analysis for LEF-1 in B cells from 2 CLL samples in nil or CpG/c treated CLL cultures after 5 days; Isotype control histogram is shaded
grey; LEF-1 histogram is black. D. Inverse correlation between LEF-1 D mean fluorescence intensity (DMFI) and IgM secretion in 14 CpG/c treated CLL
samples (best fit line equation y=20.3606Ln(x)+4.4207; r
2=0.505).
doi:10.1371/journal.pone.0026056.g003
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differentiation of CLL cells. These findings are timely due to the
known challenge of identifying therapeutic strategies to treat
refractory CLL.[31]
Our study is the first to uncover the utility of toll-like receptor
agonists in the induction of CLL ISC differentiation. We provide
evidence that CpG and CpG/c stimulation induce CLL B cells to
take on an ISC-like morphology, increase cytoplasmic Ig
Figure 4. CpG/c stimulated CLL B cells exhibit decreased
survival and decreased activation of the Wnt pathway. A. TCF/
LEF dual luciferase reporter assay relative fold change was measured in
samples from 3 CLL patients in nil or CpG/c treated cultures after 5 days
of stimulation and then 2 days in media alone (**p=.0098; error bars
represent standard error of the mean). B. CLL percent survival 48 hours
post-ficoll isolation of 5 day CpG/c stimulated or untreated samples
from 3 CLL patients (*p=.0039; error bars represent the standard error
of the mean).
doi:10.1371/journal.pone.0026056.g004
Figure 5. Multiple agents are able to induce CLL B cell
differentiation and subsequent decrease in LEF-1 expression.
A. ELISA detection of IgM levels in cell free culture supernatants from
culture of CLL cells from 6 patients. The CLL cells were either
unstimulated, or stimulated with CpG, CpG/c, TPA, interferon-alpha,
or activated T cells for 5 days of culture (error bars represent standard
error of the mean). B. Intracellular FACS LEF-1 D mean fluorescence
intensity (DMFI) was measured in the same samples (error bars
represent standard error of the mean, dashed line represents no
increase in anti-LEF-1 staining over isotype control).
doi:10.1371/journal.pone.0026056.g005
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to patient variability in the response elicited by CpG or CpG/c,
with a trend toward patients with worse prognosis (i.e., unmutated
Ig variable region) having a more robust response to TLR9
stimulation (data not shown). If this heightened TLR responsive-
ness remains in vivo for CLL patients, then CpG therapy with or
without other conventional drugs could be more effective in poor
prognosis patients. These findings add a new dimension to our
understanding of the effects of TLR agonists on CLL cells and
further support the use of TLR agonists in this mature B cell
malignancy.
LEF-1 is expressed by B cell precursors in the bone marrow and
is critical during B cell development.[8] Mature B and plasma cells
lose expression of LEF-1 during B cell development.[9] Similarly,
this study has demonstrated that stimulating CLL cells to acquire a
further stage of differentiation, i.e., ISC, leads to a decrease in
LEF-1 expression while the plasma cell specific transcription
factor, PRDM1, increases. We further verified the decrease in
LEF-1 protein via western blot and intracellular FACS analysis.
Interestingly, there was an inverse correlation between the level of
LEF-1 expression and the amount of Ig secreted by the
differentiated leukemic B cells. These observations suggest that
agents with the greatest ability to induce CLL differentiation (i.e.,
Ig secretion) would also be most effective in decreasing LEF-1
expression and CLL survival.
The canonical Wnt signaling pathway culminates in the nucleus
with alterations in transcriptional activity. As LEF-1 is a mediator
of this activity and is also decreased by the differentiation of CLL
cells, we hypothesized that there would be a decrease in the level of
Wnt pathway activation following CLL differentiation. Indeed,
TCF/LEF dual luciferase reporter assay activity was decreased
following CLL cell differentiation into ISC. Further, we have
shown that differentiated CLL cells exhibit decreased survival
compared to untreated, non-differentiated cells. As CpG has also
been shown to directly induce apoptosis in CLL cells,[15] these
direct and differentiation-induced effects of CpG on cell survival
could synergize for an effective therapy for this mature B cell
malignancy. Although the precise mechanisms that underlie
differentiation induced diminished survival requires further study,
it is intriguing to note that there may be a role for autophagy in
immune cell differentiation and cell death.[32]
Indeed, differentiation therapy has been successfully used in
certain hematological malignancies[10] and is being investigated
in the setting of cancer stem cells as a means to eradicate this
tumor population.[33,34] Differentiation therapy has many
attractive properties which include a potentially more gentle effect
on non-tumor cells of the patient compared to chemotherapy and
sensitization of differentiated cells to more conventional therapy.
The use of TLR agonists in hematopoietic malignancies has the
potential to aid any existing or augmented anti-leukemic immune
response and to sensitize the leukemic cells to such a response. In
addition, we speculate that TLR agonists could sensitize CLL B
cells to conventional drugs. In summary, our data suggest that the
role for TLR agonists as therapeutic agents in CLL needs to be
further investigated along with studies into additional differenti-
ation agents that could lead to possible therapies in CLL.
Author Contributions
Conceived and designed the experiments: AG NEK CSZ DFJ. Performed
the experiments: AG BKA RCT. Analyzed the data: AG BKA RCT.
Contributed reagents/materials/analysis tools: NEK CSZ. Wrote the
paper: AG DFJ.
References
1. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. (2001) Gene
expression profiling of B cell chronic lymphocytic leukemia reveals a
homogeneous phenotype related to memory B cells. J Exp Med 194: 1625–1638.
2. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, et al. (2003)
Identification of a global gene expression signature of B-chronic lymphocytic
leukemia. Mol Cancer Res 1: 346–361.
3. Sherborne AL, Houlston RS (2010) What are genome-wide association studies
telling us about B-cell tumor development? Oncotarget 1: 367–372.
4. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, et al. (2011)
Genome-wide association study identifies a novel susceptibility locus at 6p21.3
among familial CLL. Blood 117: 1911–1916.
5. Gutierrez A, Jr., Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, et al.
(2010) LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is
expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood
116: 2975–2983.
6. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, et al. (2010) Small
molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in
chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12: 326–335.
7. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the
Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad
Sci U S A 101: 3118–3123.
8. Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, et al. (2000) Wnt
signaling regulates B lymphocyte proliferation through a LEF-1 dependent
mechanism. Immunity 13: 15–24.
9. Travis A, Amsterdam A, Belanger C, Grosschedl R (1991) LEF-1, a gene
encoding a lymphoid-specific protein with an HMG domain, regulates T-cell
receptor alpha enhancer function [corrected]. Genes Dev 5: 880–894.
10. Nowak D, Stewart D, Koeffler HP (2009) Differentiation therapy of leukemia: 3
decades of development. Blood 113: 3655–3665.
11. Vedantham S, Gamliel H, Golomb HM (1992) Mechanism of interferon action
in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 52:
1056–1066.
12. Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR (2011)
Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs
20: 361–372.
13. Meyer T, Stockfleth E (2008) Clinical investigations of Toll-like receptor
agonists. Expert Opin Investig Drugs 17: 1051–1065.
14. Spaner DE, Masellis A (2007) Toll-like receptor agonists in the treatment of
chronic lymphocytic leukemia. Leukemia 21: 53–60.
15. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, et al. (2010)
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an
apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115:
5041–5052.
16. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, et al. (2007) The Akt
signaling pathway determines the different proliferative capacity of chronic
lymphocytic leukemia B-cells from patients with progressive and stable disease.
Leukemia 21: 110–120.
17. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, et al. (2005) B-
cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Clin Cancer Res 11: 1490–1499.
18. Zupo S, Massara R, Dono M, Rossi E, Malavasi F, et al. (2000) Apoptosis or
plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia
cells induced by cross-linking of surface IgM or IgD. Blood 95: 1199–1206.
19. Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR (1978) Induction of in
vitro differentiation and immunoglobulin synthesis of human leukemic B
lymphocytes. J Exp Med 148: 1570–1578.
20. Cossman J, Neckers LM, Braziel RM, Trepel JB, Korsmeyer SJ, et al. (1984) In
vitro enhancement of immunoglobulin gene expression in chronic lymphocytic
leukemia. J Clin Invest 73: 587–592.
21. Totterman TH, Danersund A, Carlsson M, Nilsson K (1987) Effects of
recombinant interferon-alpha and -gamma on B-CLL cells in serum-free
medium: expression of activation, differentiation, and CALLA antigens.
Leukemia 1: 667–672.
22. Carlsson M, Matsson P, Rosen A, Sundstrom C, Totterman TH, et al. (1988)
Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic
lymphocytic leukemia cells to simultaneous immunoglobulin secretion and DNA
synthesis. Leukemia 2: 734–744.
23. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, et al. (2007) CpG DNA
activation and plasma-cell differentiation of CD27- naive human B cells. Blood
109: 1611–1619.
24. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, et al. (1996)
Establishment and characterization of three myeloma cell lines that demonstrate
variable cytokine responses and abilities to produce autocrine interleukin-6.
Leukemia 10: 866–876.
25. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, et al. (2000)
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine produc-
tion, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Blood 95: 999–1006.
CLL Differentiation Induces LEF-1 Loss
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e2605626. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C (2006) Immunosti-
mulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal
aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation
to FISH, IgVH status, and CD38 expression. Blood 108: 3152–3160.
27. Put N, Konings P, Rack K, Jamar M, Van Roy N, et al. (2009) Improved
detection of chromosomal abnormalities in chronic lymphocytic leukemia by
conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimu-
lation: A Belgian multicentric study. Genes Chromosomes Cancer 48: 843–853.
28. Darce JR, Arendt BK, Chang SK, Jelinek DF (2007) Divergent effects of BAFF
on human memory B cell differentiation into Ig-secreting cells. J Immunol 178:
5612–5622.
29. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, et al. (2006)
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely
reduced in congenital neutropenia. Nat Med 12: 1191–1197.
30. Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, et al. (2007)
Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell
lymphomas. Blood 110: 2650–2658.
31. Schnaiter A, Stilgenbauer S (2010) Refractory chronic lymphocytic leukemia--
new therapeutic strategies. Oncotarget 1: 472–482.
32. Puissant A, Robert G, Auberger P (2010) Targeting autophagy to fight
hematopoietic malignancies. Cell Cycle 9: 3470–3478.
33. Wang B, Yu SC, Jiang JY, Porter GW, Zhao LT, et al. (2011) An inhibitor of
arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-
renewal of glioma stem-like cells. Stem Cell Rev 7: 458–470.
34. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009)
Identification of selective inhibitors of cancer stem cells by high-throughput
screening. Cell 138: 645–659.
CLL Differentiation Induces LEF-1 Loss
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26056